Current Research Studies

The Family Allergy & Asthma Research Institute is currently recruiting individuals who have allergic and asthmatic conditions for our active studies listed below. You do not need to be a current patient of Family Allergy & Asthma to participate in a research study.

If you are interested in participating and believe you meet the requirements, please contact our research staff to learn more at 502.368.0732.

Hereditary Angioedema (HAE) Research Study

The main purpose of this study is to investigate a potential treatment for preventing hereditary angioedema attacks (HAE) and to evaluate the safety of the investigational treatment when given for a long period of time. This study is open for participants ages 12 and up.

Study Duration:
The study will last approximately 96 weeks for participants. There will be 14 visits to the research department. Participants will be compensated for their time, travel, and meals.

If interested in participating in this clinical study, call: 502.368.0732

Request More Information About This Study

TEVA Asthma Research Study

The main purpose of this study is to demonstrate the equivalence of Fluticasone Propionate and the FDA approved drug, Flovent HFA. This study is open for adults between the ages of 18 to 75 years.

Study Duration:
The study will last between a month and a half to three months for participants. There will be 4 visits to the research department. Participants will be compensated for their time.

If interested in participating in this clinical study, call: 502.368.0732

Request More Information About This Study

Atopic Dermatitis Research Study

The main purpose of this study is to test if the study drug, tralokinumab, is better than a placebo at treating moderate to severe atopic dermatitis (a type of eczema) in adolescents between the ages of 12 to 17 years.

Study Duration:
The study will last up to 72 weeks, and there will be up to 30 visits at the clinic and 2 telephone contacts by the study staff. The visits at the clinic will typically be every second week.  There will be a possibility for transfer to known treatment of tralokinumab after 16 weeks if no response to study treatment in the previous 16 weeks.

If interested in participating in this clinical study, call: 502.368.0732

Request More Information About This Study

Severe Eosinophilic Asthma Study

Location: Louisville
Description: Observational study to evaluate effectiveness of NUCALA and to describe the use of NUCALA in real world clinical practice to provide a more complete understanding of the value of NUCALA for patients with severe eosinophilic asthma. No special tests or examinations are needed. 2 year study in which patients receive usual care from their doctor. Participants will complete questionnaires no more frequently than 3 months that take about 5 minutes to complete.
Requirements: Adults, ages 18 years or over.

  • Patient must have been diagnosed with asthma.
  • Have Anthem Insurance.
  • Physician decision to start NUCALA
  • Allow medical records to be obtained from past 12 months.

Exclusion: NUCALA injections in the past 12 months, can not have participated in another clinical trial in the past 12 months.

Request to Learn More About This Research Study

Interested in hearing more about these Research Trials?

Please contact one of our staff at 502.368.0732 or fill out the form below:

  • This field is for validation purposes and should be left unchanged.